This is a routine buyback progress update with no new material information. The program is proceeding at a steady pace with approximately 54% of the authorization utilized. Monitor future filings for any change in pace or completion of the program, but no immediate trading action is warranted.
Price Chart
Executive Summary
Novo Nordisk filed a routine 6-K disclosing weekly share repurchase transactions under its existing DKK 15 billion buyback program. Through August 14, 2026, the company has repurchased 28.9 million B shares for DKK 8.08 billion at an average price of DKK 279.80 per share. This is a routine operational update with no new financial guidance, clinical data, or strategic announcements.
Key Facts
- Novo Nordisk repurchased 1,000,000 B shares between August 10-14, 2026, for a total transaction value of DKK 301.6 million.
- Since the program's initiation on May 6, 2026, 14,125,000 B shares have been repurchased for DKK 4.28 billion.
- Overall, since February 4, 2026, Novo Nordisk has repurchased 28,884,179 B shares at an average price of DKK 279.80 per share, totaling DKK 8.08 billion.
- The total buyback authorization is up to DKK 15 billion over a 12-month period beginning February 4, 2026.
- Novo Nordisk holds 42,924,876 B shares as treasury shares, representing 1.0% of total share capital.
Financial Impact
DKK 8.08 billion deployed in buybacks since February 4, 2026, out of a DKK 15 billion authorization
Risk Factors
- No new risks identified; this is a routine operational filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005599 |
| Document: 0001171843-26-005599-index-headers.html | 0001171843-26-005599 |
| Document: 0001171843-26-005599-index.html | 0001171843-26-005599 |
| Document: 0001171843-26-005599.txt | 0001171843-26-005599 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 5d ago | 6-K | $39.13 | awaiting T+20 | awaiting T+20 | $40.00 (+2.22%) |
Oct 26, 2026 6d ago | Court Ruling | $38.67 | awaiting T+20 | awaiting T+20 | $40.00 (+3.44%) |
Oct 19, 2026 12d ago | 6-K | $38.42 | awaiting T+20 | awaiting T+20 | $40.00 (+4.11%) |
Oct 13, 2026 18d ago | 6-K | $38.06 | awaiting T+20 | awaiting T+20 | $40.00 (+5.10%) |
Oct 6, 2026 25d ago | 6-K | $37.53 | awaiting T+20 | awaiting T+20 | $40.00 (+6.58%) |
Sep 28, 2026 4w ago | 6-K | $38.71 $38.95 | ▲ +0.61% | ▲ +0.64% | $40.00 (+3.33%) |
Sep 23, 2026 5w ago | Court Ruling | $38.62 $39.43 | ▲ +2.10% | ▲ +2.52% | $40.00 (+3.57%) |
Sep 21, 2026 5w ago | 6-K | $39.80 $38.42 | ▼ −3.47% | ▼ −2.56% | $40.00 (+0.50%) |
Sep 17, 2026 6w ago | 6-K | $43.19 $39.22 | ▼ −9.19% | ▼ −10.40% | $40.00 (−7.39%) |
Sep 15, 2026 6w ago | 6-K | $42.53 $38.06 | ▼ −10.51% | ▼ −13.23% | $40.00 (−5.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers